Intravitreales bevacizumab bei der neovaskulären altersabhängigen makuladegeneration

Translated title of the contribution: Intravitreal bevacizumab for neovascular age-related macular degeneration

M. S. Ladewig, F. Ziemssen, G. Jaissle, H. M. Helb, H. P.N. Scholl, N. Eter, K. U. Bartz-Schmidt, F. G. Holz

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.

Translated title of the contributionIntravitreal bevacizumab for neovascular age-related macular degeneration
Original languageGerman
Pages (from-to)463-470
Number of pages8
Issue number6
StatePublished - Jun 2006
Externally publishedYes


  • Age-related macular degeneration (ARMD)
  • Anti-VEGF therapy
  • Antiangiogenesis
  • Bevacizumab
  • Choroidal neovascularization (CNV)
  • Pegaptanib
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intravitreal bevacizumab for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this